Article No
AFC-CGP9D7-0.1
Specifications
| Application | FC |
| Article No | AFC-CGP9D7-0.1 |
| Biosite Brand | Biosite Flow |
| Country Availability | all |
| Clone | 01G |
| Clone Type | monoclonal |
| Concentration | 1 mg/ml |
| Conjugation | FITC |
| Description | Anti-HLA-G FITC |
| Recommended Dilution | The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC. |
| Supplier | Nordic Biosite |
| Entrez Gene ID | 3135 |
| Format | FITC |
| Immunogen | HLA-B27 transgenic mice were imunized with H-2 identical murine cells transfected with and expressing genes encoding HLA-G and human beta2-microglobulin. |
| Isotype | IgG1 |
| Keywords | MHC (Major Histocompatibility Complex) and Related Antigens (Human) |
| Notes | Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage. |
| Previous Article No | AFC-5001-2, AFC-CGP9D7-0.1 |
| Product Type | Antibodies Primary |
| Protocol | Flow cytometry: Recommended dilution: 5 μg/ml. |
| Purification | Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography. |
| Research area | Immunology |
| Size | 0.1 mg |
| Source / Host | mouse |
| Species Reactivity | human |
| Storage | Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze. |
| Substrate / Buffer | Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide |
| Technical Specifications | The antibody 01G recognizes membrane-bound form of HLA-G (full-length HLA-G1), but not soluble forms. HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells. |
| UniProt Number | P17693 |
| Product Page Updated | 2024-01-03T12:18:20.318Z |
